In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic gram-positive bacteria

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 6, 2005, Pages 2498-2500

  Yoon, Eun Jeong ^a   Jo, Yeong Woo ^a,b   Choi, Sung Hak ^b   Lee, Tae Ho ^b   Rhee, Jae Keol ^b   Yoo, Moohi ^b   Shim, Mi Ja ^c   Choi, Eung Chil ^a  

^a Seoul National University   (South Korea)

^b Dong A Pharmaceutical Company   (South Korea)

^c University of Seoul   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DA 7867; LINEZOLID; OXAZOLIDINONE DERIVATIVE; UNCLASSIFIED DRUG;

AEROBIC BACTERIUM; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACETAMIDES; AEROBIOSIS; ANIMALS; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; MALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES;

EID: 19544386462     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.6.2498-2500.2005     Document Type: Article

References (17)

1. Azoulay-Dupuis, E., and P. Moine. 1999. Mouse pneumococcal pneumonia models, p. 481-493. In O. Zak and M. Sande (ed.), Handbook of animal models of infection. Academic Press, Inc., San Diego, Calif.
2. Bae, S. K., W. Chung, E. J. Kim, J. K. Rhee, J. W. Kwon, W. B. Kim, and M. G. Lee. 2004. Pharmacokinetics of DA-7867, a new oxazolidinone, after intravenous or oral administration to rats: intestinal first-pass effect. Antimicrob. Agents Chemother. 48:659-662.
3. Barrett, J. F. 2000. Linezolid Pharmacia Corp. Curr. Opin. Investig. Drugs 1:181-187.
4. Biedenbach, D. J., G. J. Moet, and R. N. Jones. 2004. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn. Microbiol. Infect. Dis. 50:59-69.
5. Clark, N. M., E. Hershberger, M. J. Zervosc, and J. P. Lynch III. 2003. Antimicrobial resistance among gram-positive organisms in the intensive care unit. Curr. Opin. Crit. Care 9:403-412.
6. Cleeland, R., and E. Squires. 1991. Evaluation of new antimicrobials in vitro and in experimental animal infections, p. 747-762. In V. Lorian (ed.), Antibiotics in laboratory medicine, Williams & Wilkins, Baltimore, Md.
7. Daly, J. S., G. M. Eliopoulos, E. Reiszner, and R. C. Moellering, Jr. 1988. Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. J. Antimicrob. Chemother. 21:721-730.
8. Gonzales, R. D., P. C. Schreckenberger, M. B. Graham, S. Kelkar, K. DenBesten, and J. P. Quinn. 2001. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357:1179.
9. Herrero, I. A., N. C. Issa, and R. Patel. 2002. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N. Engl. J. Med. 346:867-869.
10. Billiard, J. 2002. Linezolid (Zyvox). Prim. Care Update Ob/Gyns. 9:178-180.
11. Livermore, D. M. 2003. Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother. 51:9-16.
12. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
13. Neu, H. C, A. Novelli, G. Saha, and N. X. Chin. 1988. In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105. Antimicrob. Agents Chemother. 32:580-583.
14. Tsao, N., T. Luh, C. Chou, J. Wu, Y. Lin, and H. Lei. 2001. Inhibition of group A streptococcus infection by carboxyfullerene. Antimicrob. Agents Chemother. 45:1788-1793.
15. Tsiodras, S., H. S. Gold, G. Sakoulas, G. M. Eliopoulos, C. Wennersten, L. Venkataraman, R. C. Moellering, and M. J. Ferraro. 2001. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358:207-208.
16. Wisplinghoff, H., T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and M. B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.
17. Yong, D., J. H. Yum, K. Lee, Y. Chong, S. H. Choi, and J. K. Rhee. 2004. In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 48:352-357.